Introduction {#s1}
============

Vast amount of evidence demonstrates the key role of systemic immunity in tumour progression and patient outcome. Efforts to manipulate the immune response to tumours are at the core of basic and translational cancer research. In mammals and flies, tumourigenesis triggers inflammation and activation of the immune system, leading to tumour cell death ([@bib15]; [@bib44]; [@bib45]; [@bib54]). Tumour Necrosis Factor (TNF) is an important player in these tumour/immune interactions and has pleiotropic effects on tumours, including induction of cell death ([@bib22]; [@bib44]). This function is conserved in *Drosophila*, where the single TNF homolog Eiger (Egr), produced by tumour-associated macrophages (TAMs), has been shown to drive cell death of neoplastic tumours, generated in larval imaginal discs by the loss of apico-basal complex components such as Disc large 1, Scribble or Lethal giant larvae ([@bib15]; [@bib45]; [@bib46]). Moreover, we have previously reported that tumours from *disc large 1 Drosophila* mutant larvae (*dlg^40.2^* hereafter referred to as *dlg*), activate Toll pathway in the *Drosophila* fat body in an Egr-dependent manner, and this immune activation is necessary for TNF-dependent tumour cell death ([@bib45]). However, the mechanisms by which activation of an immune response in the fat body executes tumour cell death remain unknown ([Figure 1A](#fig1){ref-type="fig"}).

![*def* is induced in *dlg* mutant tumour bearing animals.\
(**A**) Working model showing the cooperation between haemocyte-derived TNF and the immune response in the fat body in tumour cell death ([@bib45]). (**B**) RT-qPCR analyses showing expression of several AMPs in the fat body of *dlg^40.2^* mutant tumour bearing larvae compared to wild-type (*w^1118^*) larvae (n = 4). (**C**) RT-qPCR analysis of *def* expression in *w^1118^* and *dlg^40.2^* whole larvae reared on antibiotics (n = 7). (**D**) RT-qPCR analysis showing *def* expression in larvae expressing a *ctrl-IR* or a *dlg-IR* in the posterior part of the wing disc (*en\>;UAS-dcr2*) (n = 3). (**E**) Schematic representation of the *def* gene locus showing mutant alleles generated (UTR: Untranslated Regions, SP: Signal Peptide, PrD: Pro-Domain, Def: Mature Defensin). Statistical analysis: B-D, Student t-test, B, \*\*\*p=0.0003, C, \*\*p=0.0074, D, \*p=0.042.](elife-45061-fig1){#fig1}

In *Drosophila* as in mammals, Toll pathway is well known to play a central role in the innate immune response to infection ([@bib36]). Downstream effectors of the Toll pathway include antimicrobial peptides (AMPs), which possess microbicidal activities against various pathogens. They display potent antimicrobial activity in vitro by disrupting negatively-charged microbial membranes. While intracellular activities have been reported, many AMPs kill pathogens by inserting into the lipid bilayer and disrupting the membrane integrity ([@bib9]). Host cells are instead protected from AMP as they are positively charged and contain cholesterol ([@bib8]). In vitro studies have revealed AMPs capacity to kill cancer cells ([@bib16]). However, whether this cancer-killing activity is a natural function of AMPs is unknown, as there are no reports on an in vivo paradigm addressing such question. Since the Toll pathway is activated in *dlg* mutant tumour bearing larvae and is required for optimal TNF-induced tumour cell death ([@bib45]), we hypothesised that AMPs may be involved in this process.

Here we show that *Drosophila defensin* is induced in the fat body and tracheal system of *dlg* mutant tumour bearing larvae. We find Defensin consistently associated to dying tumour cells. Critically, systemic and tissue specific knockdown of Defensin demonstrates a non-redundant role of the AMP in controlling tumour growth through the induction of tumour cell death. Anti-tumoural Defensin production relies on TNF-dependent activation of both Toll and Imd pathway. Our results demonstrate that *dlg* mutant tumours expose PS in response to haemocyte-derived TNF and that Defensin is present in PS enriched area on the tumour surface. Finally, we find that lack of TNF prevents PS exposure in tumours and makes them insensitive to the action of Defensin. Collectively, our results reveal an anti-tumoural role for Defensin in vivo and provide insights into the molecular mechanisms, which make tumours sensitive to the killing action of an endogenous AMP.

Results {#s2}
=======

*dlg* tumour bearing larvae express the AMP defensin {#s2-1}
----------------------------------------------------

In order to assess expression of several AMPs we performed RT-qPCR analysis on fat bodies dissected from wild type controls (*w^1118^*) or *dlg* mutant larvae ([Figure 1B](#fig1){ref-type="fig"}). Results showed consistent and statistically significant upregulation of *defensin* in fat bodies of *dlg* larvae compared to wild-type ones ([Figure 1B](#fig1){ref-type="fig"}). Other Toll-dependent AMPs display a trend to be increased (*drosomycin* and *attacin A*), even though data were highly variable amongst biological replicates, while other AMPs were not transcriptionally regulated (*drosocyn*, *cecropin A1*) ([Figure 1B](#fig1){ref-type="fig"}). Interestingly, human β-Defensin-1 displays anticancer activity in vitro ([@bib10]; [@bib53]), and deletion of human *def* appears prevalent in some cancer types ([@bib66]). This prompted us to explore the role of *Drosophila* Defensin in *dlg* mutant tumours. Using *dlg* larvae reared on antibiotics, we confirmed that *defensin* upregulation was independent of the presence of microbes ([Figure 1C](#fig1){ref-type="fig"}). Moreover, larvae bearing *dlg* imaginal discs tumours induced by RNAi (*en \>UAS-dcr2; UAS-dlg-IR*) also displayed increased *defensin* expression, confirming *def* gene induction as a consequence of *dlg*-driven epithelial transformation rather than whole body dl loss ([Figure 1D](#fig1){ref-type="fig"}). We conclude that Defensin, an AMP known for its activity against microbes, is induced, in a sterile environment, by the presence of tumours.

Defensin restrains *dlg* tumour growth and promotes tumour cell death {#s2-2}
---------------------------------------------------------------------

We next hypothesised that Defensin may be an important mediator of anti-tumour immunity in vivo. To test this hypothesis, we generated null mutant alleles for the *defensin (def)* gene using the CRISPR/Cas9 system (*def^sk3^* and *def^sk4^*) ([Figure 1E](#fig1){ref-type="fig"}) ([@bib23]). Survival analysis of *def^sk3^* flies confirmed that this AMP contribute to resist systemic infection to certain Gram-positive bacteria ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib38]). To evaluate the effect of Defensin on tumour development, we combined *def* and *dlg* loss of function alleles. Compared to *dlg* mutant animals, *dlg;def* double mutants displayed a significant increase in tumour size ([Figure 2A](#fig2){ref-type="fig"}). Tumour growth is limited by apoptotic tumour cell death as revealed by Dcp1 staining ([@bib45]). Interestingly, tumours from *dlg;def* double mutants display a very strong decrease in apoptosis ([Figure 2B--E'](#fig2){ref-type="fig"}), suggesting that increased tumour size in absence of Defensin is due to a decrease in tumour cell death. This was further supported by the similar proliferation rates measured in *dlg* and *dlg,def* mutant tumours as per quantification of anti-phophoHistone H3 staining ([Figure 2---figure supplement 1A--E'](#fig2s1){ref-type="fig"}). Importantly, the effect of Def on tumour size and cell death were still observed when *dlg* and *dlg,def* larvae were reared in sterile conditions ([Figure 2---figure supplement 1F--J'](#fig2s1){ref-type="fig"}) and further confirmed upon ubiquitous knock down of *def* using RNA interference (IR) ([Figure 2F--J'](#fig2){ref-type="fig"}). Furthermore, fat body overexpression of *def* significantly rescued tumour volume and tumour cell death of *dlg;def^sk3^* double mutant animals ([Figure 2K and L](#fig2){ref-type="fig"}). Additionally, larval injection of a synthetic Defensin peptide increased tumour cell death of *dlg* or *dlg;def^sk3^* imaginal discs ([Figure 2M](#fig2){ref-type="fig"}), while it had no effect on tissues from wild-type larvae, indicating that Defensin can selectively promote cell death of tumour cells. Altogether, these results demonstrate that Defensin is required to control *dlg*-dependent tumourigenesis in vivo through induction of tumour cell death.

![Def restricts tumour growth and promotes tumour cell death.\
(**A-E'**) Quantification of tumour volume (TV) (**A**) and tumour cell death (TCD) (**B**) in wing imaginal discs from *dlg^40.2^* (n = 17), *dlg^40.2^;def^sk3^* (n = 19) and *dlg^40.2^;def^sk4^* (n = 20) mutant larvae and representative immunofluorescence images of tissues quantified (**C--E'**). F, RT-qPCR analysis showing *def* expression upon ubiquitous knockdown (*dlg^40.2^; tub\>*) (n = 3). **G-J'**, Quantification of TV (**G**) and TCD (**H**) in wing imaginal discs from larvae ubiquitously expressing a *control-IR* (*ctrl-IR*: n = 10) or a *def-IR* (n = 15) and representative immunofluorescence images of tissues quantified (**I--J'**). **K-L**, Quantification of TV (**K**) and TCD (**L**) in wing imaginal discs from *dlg* mutant controls (*dlg^40.2^;lpp\>*: n = 28), *dlg;def^sk3^* mutants controls (*dlg^40.2^;def^sk3^;lpp\>*: n = 31) or *dlg;def^sk3^* mutants expressing *def* in the fat body (*dlg^40.2^;def^sk3^,UAS-def;lpp\>*: n = 27). **M**, Effect of PBS (ctrl) or synthetic Def injection on TCD from wild-type larvae (*w^1118^*, ctrl: n = 10, Def: n = 9), *dlg^40.2^* (ctrl: n = 10, Def: n = 10) and *dlg^40.2^;def^sk3^* (ctrl: n = 11, Def: n = 18) mutant larvae. Tissues were stained with 4',6-diamidino-2-phenylindole (DAPI, blue) for nuclei visualisation and with anti-cleaved Decapping protein 1 (Dcp1) antibody (red) to detect apoptotic cell death. Scale bars = 50 μm. Statistical analysis: A, B, K, L, One way ANOVA, \*p\<0.05, \*\*\*\*p\<0.0001; F, Student t-test, \*\*\*\*p\<0.0001, G-H, Mann-Whitney test, G, \*\*p=0.0054, H, \*\*\*\*p\<0.0001; M, Two way ANOVA (only relevant significant statistics are indicated), \*p\<0.05, \*\*\*\*p\<0.0001.](elife-45061-fig2){#fig2}

Defensin remotely produced from immune tissues bind to tumour cells {#s2-3}
-------------------------------------------------------------------

Having shown that Defensin restrict tumour growth, we sought to determine the tissues that produced endogenous Defensin in the context of tumour bearing. Previous studies have shown that Defensin is not produced by imaginal discs or tumours ([@bib11]; [@bib35]). In the context of infection, Defensin can be produced by the fat body as well the tracheal and gut epithelium ([@bib58]). We monitored *defensin* expression by RT-qPCR in various immune tissues of tumour bearing animals. We observed that the fat body, homologue to the mammalian liver and adipose tissue, and the trachea, a network of tubes transporting oxygen to cells that resembles the mammalian vasculature, were the main sources of *defensin* in these animals ([Figure 3A](#fig3){ref-type="fig"}). This was also supported by Defensin immunostaining, ([Figure 3B and C](#fig3){ref-type="fig"}). Transcript assessment upon targeted IR knock down of *defensin* in the respective tissues further confirmed the domains of endogenous gene expression ([Figure 3D and I](#fig3){ref-type="fig"}). Importantly, knocking down *defensin* expression specifically in the fat body or the trachea of *dlg* animals, resulted in increased tumour size and decreased tumour cell death ([Figure 3E--H' and J--M'](#fig3){ref-type="fig"}) confirming the non-redundant functional requirement of *defensin* in both tissues to efficiently promote tumour cell death.

![Def from the trachea and the fat body mediates tumour cell death.\
(**A**) RT-qPCR analysis of *def* expression in gut, fat body and trachea dissected from *w^1118^* or *dlg^40.2^* mutant larvae (n = 3). **B-C**, Fat body (**B**) and trachea (**C**) from *dlg^40.2^* mutant larvae stained with DAPI (blue) and anti-Def antibody (red). **D**, RT-qPCR analysis of *def* expression in *dlg^40.2^* mutant larvae (*dlg^40.2^;lpp\>*) expressing a *ctrl-IR* or *def-IR* in the fat body (n = 4). **E-H'**, Quantification of TV (**E**) and TCD (**F**) in wing imaginal discs from *dlg^40.2^* mutant larvae (*dlg^40.2^;lpp\>*) expressing a *ctrl-IR* (n = 15) or *def-IR* (n = 17) in the fat body and representative immunofluorescence images of tissues quantified (**G--H'**). **I**, RT-qPCR analysis of *def* expression in dissected trachea from *dlg^40.2^* mutant larvae (*dlg^40.2^;btl\>*) expressing a *ctrl-IR* or *def-IR* in the trachea (n = 3). **J-M'**, Quantification of TV (**J**) and TCD (**K**) in wing imaginal discs from *dlg^40.2^* mutant larvae (*dlg^40.2^;btl\>*) expressing a *ctrl-IR* (n = 14) or *def-IR* (n = 16) in the trachea and representative immunofluorescence images of tissues quantified (**L--M'**). Tumours were stained with DAPI (blue) and anti-Dcp1 antibody (red). Scale bars = 50 μm. Statistical analysis: A, D, I, Student t-test, D, \*\*p=0.0054, I, \*\*\*\*p\<0.0001; E, F, J, K, Mann-Whitney test, E, F, \*\*\*\*p\<0.0001, J, \*\*\*p=0.0009, K, \*\*\*p=0.0004.](elife-45061-fig3){#fig3}

To investigate the possibility that Defensin produced by the fat body and the trachea can specifically target tumour cells, we made use of an inducible haemagglutinin (HA) tagged form of Defensin (*UAS-def-HA*). We noticed leaky HA protein expression in the tracheal system ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) but not in the fat body ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}) of animals carrying the *UAS-def-HA* construct only. Therefore, we overexpressed *UAS-def-HA* in the fat body using a Gal4 specific driver (*lpp \>def* HA), which resulted in significant upregulation of Defensin in the fat body ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}) when compared to control conditions ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), but also maintained the leaky expression of the transgene in the trachea ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Strikingly, overexpression of *UAS-def-HA* in the fat body resulted in Defensin-HA immunostaining in transformed imaginal discs from *dlg* mutant animals ([Figure 4A--A'' and B--B''](#fig4){ref-type="fig"}) but not in normal tissues from *dlg* heterozygous animals ([Figure 4C and C'](#fig4){ref-type="fig"}).

![Def produced by immune tissues specifically targets tumour cells.\
(**A-A''**) DAPI (blue), anti-Dcp1 (green) and anti-HA antibody (red) staining of *dlg^40.2^* mutant tumour from larvae overexpressing a *def-HA* construct in the fat body and the trachea (*dlg^40.2^;lpp \>UAS-def-HA*). **B-B''**, Enlargement of inset from A'' (white outline) showing Dcp1 (**B**), Def-HA (**B'**) and merged channels (**B''**). **C-C'**, DAPI (blue), anti-Dcp1 (green) and anti-HA antibody (red) staining of *dlg^40.2^* heterozygous wing disc from larvae overexpressing *def-HA* (*dlg^40.2^/FM7;lpp \>UAS-def-HA*). **D-D''**, *dlg^40.2^* mutant tumour stained with DAPI (blue), anti-Def (red) and anti-Dcp1 (green) antibodies. **E-E''**, Enlargement of inset from **D''** (white outline) showing Dcp1 (**E**), Def (**E'**) and merged channels (**E''**). F, Quantification of colocalization between Def and Dcp1 staining (n = 10). **G-G'**, wild type (*w^1118^*) wing imaginal disc stained with DAPI (blue), anti-Def (red) and anti-Dcp1 (green) antibodies. **H-H''**, High-resolution imaging of a single dying tumour cell stained with DAPI (blue), anti-Def (red) and anti-Dcp1 (green) antibodies. A, C, D, G, Scale bars = 50 μm; B, E, Scale bars = 10 μm; H, Scale bar = 2.5 μm. Statistical analysis: F, Student t-test, \*\*p=0.0093.](elife-45061-fig4){#fig4}

Consistently, using anti-Defensin antibody, we observed endogenous Defensin staining on *dlg* mutant tumour ([Figure 4D--D'' and E--E''](#fig4){ref-type="fig"}) but not in wild-type discs ([Figure 4G,G'](#fig4){ref-type="fig"}). Interestingly, we observed Defensin preferentially bound to tumour areas enriched with apoptotic cells ([Figure 4D--D'' and E--E''](#fig4){ref-type="fig"}). This was confirmed by quantification of the amount of Def staining colocalising with Dcp1 staining ([Figure 4F](#fig4){ref-type="fig"}). High-resolution imaging showed Defensin enrichment at the membrane of these dying cells ([Figure 4H--H''](#fig4){ref-type="fig"}).

Altogether, these results show that Defensin produced by immune tissues selectively binds tumour cells to target them for apoptosis.

Toll and Imd pathway contribute to Defensin expression in *dlg* mutant larvae {#s2-4}
-----------------------------------------------------------------------------

*defensin* expression upon systemic infection relies on both Toll and Imd pathways ([@bib36]; [@bib37]). While we previously showed that Toll pathway activation in *dlg* mutant larvae is required to achieve maximal tumour cell death ([@bib45]), the involvement of the Imd pathway in tumour bearing animals was still elusive. To assess the contribution of the Imd pathway to both *defensin* expression and tumour burden, we analysed these two phenotypes in larvae deficient for the Imd-pathway. We observed a 55--60% decrease in *defensin* expression in *dlg* mutants carrying a loss of function allele affecting *imd* (*dlg;imd^1^)* ([Figure 5A](#fig5){ref-type="fig"}) or the gene encoding the downstream transcription factor Relish (*dlg;rel^E20^)* ([Figure 5F](#fig5){ref-type="fig"}). Consistently, analysis of tumour phenotypes revealed increased tumour volume and decreased tumour cell death in *dlg;imd^1^* and *dlg;rel^E20^* animals when compared with *dlg* counterparts ([Figure 5B--E' and G--J'](#fig5){ref-type="fig"}). Altogether, these data demonstrate that the Imd pathway is required for *defensin* upregulation, impairment of tumour growth and induction of tumour cell death in *dlg* mutant larvae.

![Imd pathway activation is required for *def* expression and Def-mediated tumour cell death.\
(**A**) RT-qPCR analysis of *def* expression from *dlg^40.2^* and *dlg^40.2^;imd^1^* mutant larvae (n = 4). **B-E'**, Quantification of TV (**B**) and TCD (**C**) in wing imaginal discs from *dlg^40.2^* (n = 15) and *dlg^40.2^;imd^1^* (n = 14) mutants larvae and representative immunofluorescence images of tissues quantified stained with DAPI (blue) and anti-Dcp1 antibody (red) (**D--E'**). **F**, RT-qPCR analysis showing *def* expression in *dlg^40.2^* and *dlg^40.2^; rel^E20^* mutant animals (n = 5). **G-J'**, Quantification of TV (**G**) and TCD (**H**) from *dlg^40.2^* (n = 12) and *dlg^40.2^;rel^E20^* (n = 10) mutant larvae and representative pictures of the corresponding tumours (**I--J'**). Scale bars = 50 μm. Statistical analysis: A, F, Student t-test, A, \*\*\*p\<0.0003, F, \*\*\*\*p\<0.0001; B, C, G, H, Mann-Whitney test, B, C, H, \*\*\*\*p\<0.0001, G, \*\*p=0.009.](elife-45061-fig5){#fig5}

Upon infection, AMP expression in the trachea exclusively relies on the Imd pathway ([@bib58]). We therefore looked at *defensin* expression and tumour phenotype in *dlg* mutant larvae where *imd* expression had been knocked down specifically within tracheal cells (*dlg;btl \>imd-IR*). In this setting, *defensin* expression was significantly reduced in the whole larvae ([Figure 6A](#fig6){ref-type="fig"}). Consistently, tumour volume was increased while tumour cell death was decreased ([Figure 6B--E'](#fig6){ref-type="fig"}) showing the requirement of Imd pathway in the tracheal system to control tumour burden.

![Imd and Toll pathway activation are required in the trachea and the fat body to promote Defensin-dependent tumour cell death.\
(**A**) RT-qPCR analysis of *def* expression from *dlg^40.2^* mutant larvae (*dlg^40.2^;btl\>*) expressing a *ctrl-IR* or *imd-IR* in the trachea (n = 3). **B-E'**, Quantification of TV (**B**) and TCD (**C**) from *dlg^40.2^* mutant larvae (*dlg^40.2^;btl\>*) expressing a *ctrl-IR* (n = 18) or *imd-IR* (n = 15) in the trachea and representative immunofluorescence images of tissues quantified stained with DAPI (blue) and anti-Dcp1 antibody (red) (**D--E'**). **F**, RT-qPCR analysis of *def* expression from *dlg^40.2^* mutant larvae (*dlg^40.2^;lpp\>*) expressing a *ctrl-IR*, an *imd-IR* or a *myd88-IR* in the fat body. **G-K'**, Quantification of TV (**G**) and TCD (**H**) from *dlg^40.2^* mutant larvae (*dlg^40.2^;lpp\>*) expressing a *ctrl-IR*, an *imd-IR* or a myd88-IR in the fat body and representative immunofluorescence images of tissues quantified (**I--K'**). **L-O**, Quantification of TV (**L, N**) and TCD (**M, O**) from *dlg^40.2^* mutant larvae (*dlg^40.2^;lpp\>*) expressing a *ctrl-IR*, an *imd-IR* alone or in combination with a *UAS-def* in the fat body (**L, M**) and from *dlg^40.2^* mutant larvae (*dlg^40.2^;lpp\>*) expressing a *ctrl-IR*, a *myd88-IR* alone or in combination with a *UAS-def* in the fat body (**N, O**). Scale bars = 50 μm. Statistical analysis: A, Student t-test, A, \*\*\*p=0.0001; B, C, Mann-Whitney test, B, \*\*\*p=0.0003, C, \*\*\*p=0.0002; F, G, H, L-O, One way ANOVA, \*p\<0.05, \*\*p\<0.01, \*\*\*\*p\<0.0001.](elife-45061-fig6){#fig6}

In the fat body, both Imd and Toll pathways contribute to AMPs expression during infection ([@bib59]). To evaluate the contribution of Toll and Imd pathways in fat body in tumour bearing larvae, we monitored *defensin* expression and tumour phenotype in *dlg* animals in which Toll or Imd pathways have been selectively knocked down in the fat body. Knocking down *myd88,* which encodes a common adaptor to Toll receptors ([@bib29]), or *imd* in the fat body resulted in a significant decrease in *defensin* expression ([Figure 6F](#fig6){ref-type="fig"}) and, consistently, increased tumour volume and decreased tumour cell death ([Figure 6G--K'](#fig6){ref-type="fig"}). Moreover, concomitant overexpression of *defensin* and *Myd88-IR* or *Imd-IR* in the fat body of *dlg* larvae was sufficient to significantly rescue the tumour volume and tumour cell death phenotypes resulting from fat body knockdown of *Myd88* or *Imd* in *dlg* animals ([Figure 6L--O](#fig6){ref-type="fig"}).

We conclude that, in *dlg* mutant animals, Toll and Imd pathways have non-redundant roles in restricting tumour growth and promoting tumour cell death through the control of *defensin* expression. Importantly, forced *defensin* expression in an otherwise immune-compromised animal is sufficient to reduce tumour growth and to promote tumour cell death.

Defensin is enriched in tumour areas exposing phosphatidylserine {#s2-5}
----------------------------------------------------------------

AMPs targeting of pathogens, involves the recognition of negatively charged molecules exposed on the cell surface ([@bib67]). A key question raised by our study is how Defensin can selectively bind and kill tumour cells ([Figure 4](#fig4){ref-type="fig"} and [Figure 2M](#fig2){ref-type="fig"}). Selective action of cationic AMP is attributed to their ability to interact with negatively charged membrane such as those found in bacteria. We hypothesised that the membrane of tumour cells from *dlg* mutant larvae might change their electrostatic properties, making them sensitive to the action of Defensin. Phosphatidylserine (PS) is a negatively charged phospholipid, normally restricted to the inner leaflet of the cell membrane. However, PS can be exposed on the outer leaflet for example in apoptotic cells, which tags these cells for phagocytosis ([@bib6]; [@bib51]; [@bib57]). Moreover, PS exposure has been shown to occur independently of apoptosis in many cancer cell types ([@bib48]). Therefore, we investigated whether PS externalisation could be a factor allowing specific targeting of tumour cells by Defensin. Our data revealed that *dlg* but not wild-type tissues, displayed high levels of Annexin V staining ([Figure 7A and F](#fig7){ref-type="fig"}; compare to E), indicating increased exposure of PS by *dlg* tumours. We next looked at the ability of Defensin to specifically associate with tumour cells exposing PS and found that Defensin was enriched in Annexin V^+ve^ areas on *dlg* tumours ([Figure 7A--A'' and B--B''](#fig7){ref-type="fig"}). This was confirmed by quantification of the amount of Def staining colocalising with Annexin V staining ([Figure 7C](#fig7){ref-type="fig"}). Thus, Defensin produced by immune responsive tissues binds specifically to tumour cells and this ability correlated with their exposure of PS.

![TNF is required for PS exposure and Defensin-driven tumour cell death.\
(**A-A''**) DAPI (blue), Annexin V (green) and anti-Def (red) staining of *dlg^40.2^* mutant tumours. (**B-B''**) Enlargement of inset from **A''** (white outline) showing Annexin V (**B**), Def (**B'**) and merged channels (**B''**). (**C**) Quantification of colocalisation between Def and Annexin V staining (n = 18). (**D**) RT-qPCR analysis showing *def* expression in wild-type, *dlg^40.2^* or *dlg^40.2^;egr^3^* mutants. (**E- G**) Annexin V (green) and DAPI (blue) staining of wing imaginal discs from larvae of the indicated genotypes. (**H, I**) Annexin V (green) and DAPI (blue) staining of wing imaginal discs from *dlg* mutant larvae (*dlg^40.2^,hml\>*) expressing a *ctrl-IR* (n = 5) or an *egr-IR* (n = 9) in the haemocytes. (**J**) Quantification of Annexin V signal on tumours from the corresponding genotypes. (**K**) Quantification of TCD upon PBS (ctrl) or Def injection in wild-type (*w^1118^*, ctrl: n = 10, Def: n = 14), *dlg^40.2^* (ctrl/Def: n = 18) or *dlg^40.2^;egr^3^* (ctrl: n = 20, Def: n = 13) mutant larvae. (**L**) A model for Def antitumoural activity. A, E-I, Scale bars = 50 μm; B, Scale bars = 20 μm. Statistical analysis: C, Student t-test, \*\*\*\*p\<0.0001; D, One way ANOVA, \*p\<0.05; J, Mann-Whitney test, \*\*\*p=0.001; K, Two way ANOVA (only relevant significant statistics are indicated), \*p\<0.05.](elife-45061-fig7){#fig7}

The TNF homolog Eiger is required for PS exposure and defensin anti-tumoural activity {#s2-6}
-------------------------------------------------------------------------------------

Previous studies have shown that circulating macrophage-like cells in *Drosophila,* called haemocytes, bind to *dlg* mutant tumours and contribute to cell death ([@bib45]). This process is mediated by the release of Egr from haemocytes ([@bib15]; [@bib45]), which then activates the JNK pathway in target cells to promote apoptosis ([@bib28]). Moreover, Toll pathway activation in tumour bearing animals also requires Egr ([@bib45]). Accordingly, we found that *defensin* upregulation observed in *dlg* animals was lost in *dlg;egr^3^* double mutants ([Figure 7D](#fig7){ref-type="fig"}). We next tested whether PS exposure in tumours was dependent on Eiger, and observed an almost complete loss of cell-surface PS in *dlg;egr^3^* tumours ([Figure 7E--G](#fig7){ref-type="fig"}). Therefore, Egr is required for PS exposure in these tumours. We then analysed PS exposure in *dlg* mutant tumours, upon specific *egr* knockdown in haemocytes (*dlg;hml \>egr-IR*), and observed a strong decrease in cell surface-exposed PS compared to control tumours (*dlg;hml \>ctrl-*IR) ([Figure 7H--J](#fig7){ref-type="fig"}). This indicates that PS exposure in tumour cells is likely triggered by the release of Egr from haemocytes. Finally, to further test the hypothesis that Def requires PS to bind to tumours, we assessed the ability of overexpressed Def-HA to bind to *dlg,egr^3^* mutant tumours. Consistently with the observed basal and overexpressed Def-HA expression pattern in wild type tissues ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), Def-HA was expressed in the trachea and fat body of *dlg,egr^3^* mutant animals ([Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}). However, we did not find any detectable association of Def-HA to the surface of *dlg,egr^3^* tumours ([Figure 7---figure supplement 1C,C'](#fig7s1){ref-type="fig"}).

Importantly, Egr-dependent signalling and PS exposure were intact in *dlg;def* and *dlg;imd* mutants ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}) indicating that both events precede the action of Defensin in *dlg* tumours. To further assess whether Egr was required for Defensin-induced tumour cell death, we injected synthetic Defensin peptide into control, *dlg* or *dlg;egr^3^* mutant larvae. While, Defensin injection was able to robustly promote tumour cell death in *dlg* mutant tumours, it was unable to affect tumours derived from Egr-deficient animals, further demonstrating the requirement of Egr for tumour cell death induced by Defensin ([Figure 7K](#fig7){ref-type="fig"}).

Finally, we tested whether the antitumoral action of Def extended to other tumour models. We observed that tumours induced by the loss of *scribble* (*scrib*), another member of the same apico-basal complex as *dlg,* showed significant cell surface PS exposure, which was Egr dependent ([Figure 7---figure supplement 3A,A'](#fig7s3){ref-type="fig"}; compare to [Figure 7---figure supplement 3B,B'](#fig7s3){ref-type="fig"}). Moreover, we detected Def enrichment in areas positive for Dcp1 staining on *scrib* tumours ([Figure 7---figure supplement 3C--C'' and D--D''](#fig7s3){ref-type="fig"}). Consistently, removing *def* from *scrib* mutant animals led to increase in tumour volume and decrease in tumour cell death ([Figure 7---figure supplement 3E--H'](#fig7s3){ref-type="fig"}). Altogether, these results show that the sensitivity to Def is not restricted to *dlg* mutant tumours but might rather be a general feature of neoplastic growth induced by loss of cell polarity.

Discussion {#s3}
==========

While the role of antimicrobial peptides in innate immune defense has been well-recognised for decades ([@bib2]), recent reports revealed potential additional physiological functions of AMPs, including ageing and neurodegeneration ([@bib13]; [@bib34]; [@bib39]), wound-healing ([@bib14]; [@bib56]), resistance to oxidative stress ([@bib41]; [@bib68]), immune signaling ([@bib55]; [@bib61]) and anti-cancer activity ([@bib16]). However, due to the absence of AMP mutants, most of these studies have relied on the use of exogenous sources of AMPs or genetic modification of upstream regulators of AMP expression. Recently, the use of loss of function alleles of *Drosophila* Diptericin (DptB), allowed to establish a role for the AMP in long-term memory ([@bib3]). Pioneer work reporting systematic deletion of multiple AMPs in *Drosophila*, opens the door for in-depth analysis of the endogenous functions of these molecules ([@bib23]). Using such tools and a genetically defined in vivo tumour model, our study demonstrates a role for Defensin in the control of tumours and deciphers the molecular mechanism allowing specific tumour cell targeting by the AMP. Collectively, our results suggest that the two branches of *Drosophila* innate immunity contribute to tumour elimination ([Figure 7L](#fig7){ref-type="fig"}). The cellular immune response to tumours involves the binding of haemocytes to tumour cells and activation of TNF pathway leading to PS exposure ([Figure 7L](#fig7){ref-type="fig"}). This is followed by a humoral response in distant tissues (fat body and trachea) that triggers tumour cell death through the action of Defensin ([Figure 7L](#fig7){ref-type="fig"}).

A role for a *Drosophila* AMP in tumour control {#s3-1}
-----------------------------------------------

Using mutants as well as ubiquitous or targeted knockdowns, our study reveals that Defensin is non-redundantly required to drive tumour cell death and restrict tumour growth in neoplastic tumours generated by loss the apico-basal determinant Dlg and Scrib. This was reinforced by detection of Defensin on dying tumour cells as well as genetic rescue and injection experiments showing that Defensin can actively drive tumour cell death. Several in vitro studies in mammals have pointed to AMPs anti-tumoural potential ([@bib16]). Amongst these suggested anticancer peptides, Human β-Defensin-1 (hBD1) appears downregulated in 82% of prostate cancer and 90% of renal clear cell carcinomas ([@bib18]). Furthermore, expression of hBD1 induces cell death in prostate and renal cancer cells in vitro ([@bib10]; [@bib53]). Moreover, a recent report shows prevalent deletion of Human *defensin* gene cluster in some tumour types including prostate, lung and colorectal cancers, as well as a decrease overall survival in patients carrying these deletions ([@bib66]). However, since the classification of a molecule as AMP is based on structural protein features, it is important to mention that Human Defensins are not homologous of, but rather have structural resemblances, to *Drosophila* AMPs due to convergent evolution ([@bib50]). Further studies are required to determine if anticancer activity displayed by Defensins from different species is linked to their structural properties.

As upon infection ([@bib58]), we show that the fat body and the trachea are the main sources of Defensin in tumour bearing larvae. Moreover, our results indicated that Defensin's maximal expression and anti-tumour properties rely on Imd and Toll pathways activation. As expected from previous studies on anti-pathogenic immunity, Imd appears to play a critical role in the tracheal system, while both Imd and Toll drive Defensin expression in the fat body ([@bib24]; [@bib59]). Consistently, overexpressing Defensin partially rescued the effect of Imd or Toll knockdown on *dlg* tumours. However, Toll and Imd pathways are major regulators of multiple AMPs in the *Drosophila* fat body. Then, it is conceivable that AMPs other than Defensin may possess similar anti-tumoural activity. In fact, a recent study in *Drosophila* shows that ectopic expression of several antimicrobial peptides, including Defensin, can increase cell death in a haematopoietic tumour model ([@bib1]). Authors of that study also reported activation of Toll and Imd pathways together with increased expression of several AMPs in those tumour bearing animals. Together with our study, this suggests potentially general anti-tumoural properties of *Drosophila* AMPs.

Defensin specifically targets tumour cells {#s3-2}
------------------------------------------

Importantly, we show that Defensin targets tumour cells for apoptosis while sparing normal cells. As their human counterparts, we show that *Drosophila* tumours can expose PS independently of cell death ([@bib48]). Interestingly, an in vitro study showed selective anticancer activity of some synthetic peptides derived from beetle Defensin, against cancer cells exposing PS ([@bib30]). A similar targeting mechanism has also been proposed to explain temporin-1CEa or L-K6 anticancer activities towards melanoma cells and breast cancer cells respectively ([@bib62]; [@bib63]). PS is a mark of apoptotic cells, which is used as an 'eat me' signal by phagocytes ([@bib51]; [@bib57]). In *Drosophila*, the phagocytic receptor Simu together with Draper contribute to the elimination of apoptotic cells through recognition of PS ([@bib51]; [@bib57]). It would be interesting to test the role of these receptors in the control of tumour progression in *Drosophila*.

Our results indicate that PS exposure precedes Defensin action and is not just an 'eat-me' signal but likely contributes to changing the membrane of tumour cells making them sensitive to the action of AMPs. It is tempting to speculate that the deleterious effect of AMPs observed upon ageing or neurodegeneration may involve a similar targeting mechanism of 'foreign-looking' or unfit cells ([@bib12]; [@bib34]; [@bib39]).

Noteworthy, other negatively charged molecules enriched on tumour surface such as heparan sulfates and O-glycosylated mucins may also contribute to the targeting by AMPs ([@bib25]; [@bib33]).

Defensin action requires TNF {#s3-3}
----------------------------

TNF is a major player in the tumour microenvironment by exerting pleiotropic effects on both the tumour and its surroundings ([@bib22]; [@bib44]). In our *dlg* mutant model, we observed that defensin induction requires TNF, supporting previous observations that induction of innate immune response in tumour bearing animal relied on Egr produced by the tumour ([@bib45]). Indeed, Toll activation in the fat body has been proposed to be a consequence of tumour-derived TNF, which drives haemocyte proliferation leading to an increase in Toll ligand Spatzle ([@bib45]). Whether Imd pathway is also indirectly activated by the changes in immune cell activity in response to tumour or by alternative mechanisms remains an open question.

Our results show that haemocyte-derived TNF is required for PS exposure by the tumour, a key process for tumour targeting by Defensin. Consistently, haemocyte-derived TNF is shown to drive cell death in *dlg* mutant tumours ([@bib45]). The precise molecular mechanisms driving PS exposure downstream of TNF remain unknown. However, haemocyte-derived TNF, activates JNK pathway, which triggers many changes in tumour cells including apoptosis ([@bib26]; [@bib42]), ROS production ([@bib21]; [@bib49]), loss of cell polarity ([@bib69]), modification of extracellular matrix ([@bib60]), proliferation and cell migration ([@bib4]; [@bib27]; [@bib47]; [@bib52]). Mild activation of JNK on its own is insufficient to drive PS exposure and tissue sensitivity to Defensin-induced cell death (data not shown). While a JNK-independent role of Egr in PS exposure and sensitivity to the AMP cannot be ruled out, TNF might also sensitise cells through activation of the JNK pathway ([@bib15]) and PS exposure, thus providing a secondary sensitisation mechanism of tumour cells to the action of Defensin. Further studies are needed to explore a potential link between JNK activation and PS exposure.

Another consequence of TNF-dependent JNK activation in tumours is the increased expression of matrix metalloproteases (Mmps) by tumour cells ([@bib60]). Importantly, we show that Mmp-1 induction and then JNK pathway activation are still present in tumour from larvae devoided of Defensin. This demonstrates that TNF signalling acts upstream of Defensin. Mmps degrade the basal membrane facilitating metastasis of primary tumour cells ([@bib4]; [@bib47]; [@bib52]). Interestingly, a study reported that human Mmp-7 can cleave immature Defensins, promoting their activation ([@bib64]; [@bib65]). Indeed, the pro-domain present in AMPs is thought to keep their in vivo activity silent, allowing local activation of AMP upon cleavage. While the mechanisms of *Drosophila* Defensin pro-domain cleavage remain unknown, it would be interesting to explore whether the changes in the tumour microenvironment could also affect Defensin activation.

In conclusion, our study provides the first direct in vivo demonstration of the role of an endogenous AMP as an anti-cancer agent in *Drosophila*. Our data point to a conserved mechanism of tumour control by AMPs, a potent arm of the innate immune system. Importantly, we identify cellular features within tumours, which may be predictive of their sensitivity to be targeted by AMPs. This study provides a new paradigm to decipher the molecular mechanisms influencing anti-tumoural functions of an AMP, which may extend to other non-canonical roles of AMPs, such as in ageing, long-term memory and wound healing. Moreover, together with the new genetic tools allowing targeting of all *Drosophila* AMPs ([@bib23]), our study establishes new bases to explore in vivo a potential important natural mechanism of defence against tumours.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                 Designation                                             Source or reference                     Identifiers                                                                                    Additional\
  (species) or resource                                                                                                                                                                                                                        information
  --------------------------------------------- ------------------------------------------------------- --------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------
  Genetic reagent (*Drosophila melanogaster*)   w^1118^                                                 ([@bib17])                              BDSC: 3605; RRID:[BDSC_3605](https://scicrunch.org/resolver/BDSC_3605)                         

  Genetic reagent (*Drosophila melanogaster*)   w^1118^ iso                                             ([@bib20])                              N/A                                                                                            

  Genetic reagent (*Drosophila melanogaster*)   dlg^40.2^/FM7                                           ([@bib40])                              Flybase_FBal0240608                                                                            

  Genetic reagent (*Drosophila melanogaster*)   FRT82B,scrib^1^/TM6                                     ([@bib5])                               Flybase_FBal0103577                                                                            

  Genetic reagent (*Drosophila melanogaster*)   egr^3^                                                  ([@bib26])                              Flybase_FBal0147163                                                                            

  Genetic reagent (*Drosophila melanogaster*)   imd^1^                                                  ([@bib37])                              Flybase\_\                                                                                     
                                                                                                                                                FBal0045906                                                                                    

  Genetic reagent (*Drosophila melanogaster*)   rel^E20^                                                ([@bib37])                              DGGR: 109927;\                                                                                 
                                                                                                                                                RRID:[DGGR_109927](https://scicrunch.org/resolver/DGGR_109927)                                 

  Genetic reagent (*Drosophila melanogaster*)   def^sk3^                                                ([@bib23])                              N/A                                                                                            

  Genetic reagent (*Drosophila melanogaster*)   def^sk4^                                                ([@bib23])                              N/A                                                                                            

  Genetic reagent (*Drosophila melanogaster*)   btl-gal4,UAS-RFP/CyO                                    Irene Miguel-Aliaga                     N/A                                                                                            

  Genetic reagent (*Drosophila melanogaster*)   lpp-gal4/TM6B                                           ([@bib7])                               N/A                                                                                            

  Genetic reagent (*Drosophila melanogaster*)   tub-gal4                                                Bloomington *Drosophila* Stock Center   BDSC: 5138; RRID:[BDSC_5138](https://scicrunch.org/resolver/BDSC_5138)                         y(1) w\[\*\]; P{w\[+mC\]=tubP-GAL4}LL7/TM3, Sb(4) Ser(1)

  Genetic reagent (*Drosophila melanogaster*)   hml^Δ^-gal4,UAS-gfp                                     Bruno Lemaitre                          N/A                                                                                            

  Genetic reagent (*Drosophila melanogaster*)   en-gal4                                                 Bloomington *Drosophila* Stock Center   BDSC: 30564; RRID:[BDSC_30564](https://scicrunch.org/resolver/BDSC_30564)                      *y1 w\*; P{w + mW.hs=en2.4 GAL4}e16E*

  Genetic reagent (*Drosophila melanogaster*)   UAS-def IR                                              Vienna *Drosophila* Resource Centre     VDRC: 102437; RRID:[Flybase_FBst0474306](https://scicrunch.org/resolver/Flybase_FBst0474306)   P{KK111656}VIE-260B

  Genetic reagent (*Drosophila melanogaster*)   UAS-imd IR                                              Vienna *Drosophila*\                    VDRC: 101834; RRID:[Flybase_FBst0473707](https://scicrunch.org/resolver/Flybase_FBst0473707)   P{KK109863}VIE-260B
                                                                                                        Resource Centre                                                                                                                        

  Genetic reagent (*Drosophila melanogaster*)   UAS-myd88 IR                                            Vienna *Drosophila* Resource Centre     VDRC: 25402; RRID:[Flybase_FBst0455868](https://scicrunch.org/resolver/Flybase_FBst0455868)    w^1118^; P{GD9716}v25402

  Genetic reagent (*Drosophila melanogaster*)   UAS-dlg IR                                              Vienna *Drosophila* Resource Centre     VDRC: 41136; RRID:[Flybase_FBst0463952](https://scicrunch.org/resolver/Flybase_FBst0463952)    w^1118^; P{GD4689}v41136/TM3

  Genetic reagent (*Drosophila*\                UAS-egr IR                                              Vienna *Drosophila* Resource Centre     VDRC: 108814; RRID:[Flybase_FBst0480608](https://scicrunch.org/resolver/Flybase_FBst0480608)   P{KK103432}VIE-260B
  *melanogaster*)                                                                                                                                                                                                                              

  Genetic reagent (*Drosophila melanogaster*)   UAS-w IR                                                Bloomington *Drosophila* Stock Center   BDSC: 25785; RRID:[BDSC_25785](https://scicrunch.org/resolver/BDSC_25785)                      y(1) v(1); P{y\[+t7.7\] v\[+t1.8\]=TRiP.JF01786}attP2

  Genetic reagent (*Drosophila melanogaster*)   UAS-def                                                 ([@bib58])                              Flybase_FBal0145092                                                                            

  Genetic reagent (*Drosophila melanogaster*)   UAS-def-3xHA                                            FlyORF                                  FlyORF: F002467;\                                                                              M{UAS-Def.ORF.3xHA.GW}ZH-86Fb
                                                                                                                                                RRID:[Flybase_FBal0298643](https://scicrunch.org/resolver/Flybase_FBal0298643)                 

  Genetic reagent (*Drosophila melanogaster*)   UAS-dcr2                                                Bloomington *Drosophila* Stock Center   BDSC: 24650; RRID:[BDSC_24650](https://scicrunch.org/resolver/BDSC_24650)                      w\[1118\]; P{w\[+mC\]=UAS-Dcr-2.D}2

  Genetic reagent (*Drosophila melanogaster*)   spz^M7^                                                 ([@bib43])                              N/A                                                                                            

  Antibody                                      Anti-GFP (Chicken polyclonal)                           Abcam                                   Cat\# ab13970; RRID:[AB_300798](https://scicrunch.org/resolver/AB_300798)                      IF(1:4000)

  Antibody                                      Anti-Def (Mouse polyclonal)                             Dahua Chen ([@bib31])                   N/A                                                                                            IF(1:100)

  Antibody                                      Anti-HA (Mouse monoclonal)                              Cell Signaling Technology               Cat\# 2367, RRID:[AB_10691311](https://scicrunch.org/resolver/AB_10691311)                     IF(1:1000)

  Antibody                                      Anti-dcp1 (Rabbit polyclonal)                           Cell Signaling Technology               Cat\# 9578, RRID:[AB_2721060](https://scicrunch.org/resolver/AB_2721060)                       IF(1:100)

  Antibody                                      Anti-phospho-Histone H3 (Ser10) (Rabbit polyclonal)     Cell Signaling Technology               Cat\# 9701, RRID:[AB_331535](https://scicrunch.org/resolver/AB_331535)                         IF(1:100)

  Antibody                                      Anti-phospho-Histone H3 (Ser28) (Rabbit polyclonal)     Cell Signaling Technology               Cat\# 9713, RRID:[AB_823532](https://scicrunch.org/resolver/AB_823532)                         IF(1:100)

  Antibody                                      Anti-Mmp1 (Mouse clonality unknown)                     Developmental Studies Hybridoma Bank    Cat\# 3B8D12, RRID:[AB_579781](https://scicrunch.org/resolver/AB_579781)                       IF(1:10)

  Antibody                                      Anti-Chicken IgY Alexa 488\                             Molecular Probes                        Cat\# A-11039, RRID:[AB_142924](https://scicrunch.org/resolver/AB_142924)                      IF(1:500)
                                                (Goat polyclonal)                                                                                                                                                                              

  Antibody                                      Anti-Mouse IgG Alexa 488 (Goat polyclonal)              Molecular Probes                        Cat\# A-11029, RRID:[AB_138404](https://scicrunch.org/resolver/AB_138404)                      IF(1:500)

  Antibody                                      Anti-Mouse IgG Alexa 594\                               Molecular Probes                        Cat\# A-11032, RRID:[AB_141672](https://scicrunch.org/resolver/AB_141672)                      IF(1:500)
                                                (Goat polyclonal)                                                                                                                                                                              

  Antibody                                      Anti-Rabbit IgG Alexa 488 (Goat polyclonal)             Molecular Probes                        Cat\# A-11008, RRID:[AB_143165](https://scicrunch.org/resolver/AB_143165)                      IF(1:500)

  Antibody                                      Anti-Rabbit IgG Alexa 594\                              Thermo Fischer Scientific               Cat\# A-11037, RRID:[AB_2534095](https://scicrunch.org/resolver/AB_2534095)                    IF(1:500)
                                                (Goat polyclonal)                                                                                                                                                                              

  Sequence-based reagent                        rpl32-fwd                                               This paper                              PCR primers                                                                                    AGGCCCAAGATCGTGAAGAA

  Sequence-based reagent                        rpl32-rev                                               This paper                              PCR primers                                                                                    TGTGCACCAGGAACTTCTTGA

  Sequence-based reagent                        def-fwd                                                 This paper                              PCR primers                                                                                    CTTCGTTCTCGTGGCTATCG

  Sequence-based reagent                        def-rev                                                 This paper                              PCR primers                                                                                    ATCCTCATGCACCAGGACAT

  Sequence-based reagent                        def-PCR-fwd                                             This paper                              PCR primers                                                                                    TTATTGCAGAAACGGGCTCT

  Sequence-based reagent                        def-PCR-rev                                             This paper                              PCR primers                                                                                    ATGGTAAGTCGCTAACGCTAATG

  Sequence-based reagent                        def-seq                                                 This paper                              Sequencing primers                                                                             CGTGTCTTCCTGCACAGAAA

  Sequence-based reagent                        attA-fwd                                                This paper                              PCR primers                                                                                    ATGCTCGTTTGGATCTGACC

  Sequence-based reagent                        attA-rev                                                This paper                              PCR primers                                                                                    TCAAAGAGGCACCATGACCAG

  Sequence-based reagent                        cecA1-fwd                                               This paper                              PCR primers                                                                                    CTCAGACCTCACTGCAATAT

  Sequence-based reagent                        cecA1-rev                                               This paper                              PCR primers                                                                                    CCAACGCGTTCGATTTTCTT

  Sequence-based reagent                        dro-fwd                                                 This paper                              PCR primers                                                                                    CGTTTTCCTGCTGCTTGCTT

  Sequence-based reagent                        dro-rev                                                 This paper                              PCR primers                                                                                    GGCAGCTTGAGTCAGGTGAT

  Sequence-based reagent                        drs-fwd                                                 This paper                              PCR primers                                                                                    CTCTTCGCTGTCCTGATGCT

  Sequence-based reagent                        drs-rev                                                 This paper                              PCR primers                                                                                    ACAGGTCTCGTTGTCCCAGA

  Peptide, recombinant protein                  *Drosophila* endogenous Defensin                        Bulet EIRL                              N/A                                                                                            

  Peptide, recombinant protein                  *Drosophila* Synthetic Defensin                         Genepep                                 N/A                                                                                            ATCDLLSKWNWNHTACAGHCIAKGFKGGYCNDKAVCVCRN

  Commercial assay or kit                       High Capacity cDNA Reverse\                             Applied Biosystems                      Cat\# 4368813                                                                                  
                                                Transcription Kit                                                                                                                                                                              

  Commercial assay or kit                       PerfeCTa SYBR Green FastMix (Low ROX)                   Quanta Bio                              Cat\# 95074--012                                                                               

  Commercial assay or kit                       TRIzol Reagent                                          Thermo Fisher Scientific                Cat\# 15596018                                                                                 

  Commercial assay or kit                       Turbo DNA free Kit                                      Life Technologies LTD                   Cat\# AM1907                                                                                   

  Commercial assay or kit                       High Capacity cDNA Reverse Transcription Kit            Applied Biosystems                      Cat\# 4368813                                                                                  

  Chemical compound, drug                       4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI)   Sigma                                   Cat\# D9542                                                                                    1 μg/mL

  Software, algorithm                           Fiji                                                    NIH                                     <https://fiji.sc/>                                                                             

  Software, algorithm                           GraphPad Prism 6                                        GraphPad                                RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                                   

  Software, algorithm                           7500 Real-Time PCR Software                             Applied Biosystems                      RRID:[SCR_014596](https://scicrunch.org/resolver/SCR_014596)                                   

  Software, algorithm                           BatchQuantify                                           ([@bib32])                              <https://github.com/emltwc/2018-Cell-Stem-Cell>                                                

  Software, algorithm                           GraphPad Prism 6                                        GraphPad                                RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                                   

  Software, algorithm                           Volocity 3D Image Analysis Software                     Perkin Elmer                            RRID:[SCR_002668](https://scicrunch.org/resolver/SCR_002668)                                   

  Software, algorithm                           ZEN two lite                                            Zeiss                                   RRID:[SCR_013672](https://scicrunch.org/resolver/SCR_013672)                                   

  Other                                         RNasine Plus RNase Inhibitor                            Promega                                 Cat\# N261                                                                                     

  Other                                         Vectashield mounting media                              Vector Laboratories, Inc.               Cat\# H-1000--10                                                                               

  Other                                         Annexin V, Alexa Fluor 568 conjugate                    Life Technologies LTD                   Cat\# A13202                                                                                   1:20

  Other                                         Annexin V, Alexa Fluor 488 conjugate                    Life Technologies LTD                   Cat\# A13201                                                                                   1:20

  Other                                         Penicillin-Streptomycin (10,000 U/mL)                   Thermo Fisher\                          Cat\# 15140122                                                                                 Pen: 100 IU/mL\
                                                                                                        Scientific                                                                                                                             Strep: 100 mg/mL

  Other                                         PfuUltra II Fusion HS DNA Polymerase                    Agilent                                 Cat\# 600670                                                                                   

  Other                                         AnnexinV binding buffer                                 Fisher Scientific                       Cat\# BDB556454                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Drosophila* housekeeping and rearing {#s4-1}
-------------------------------------

Flies were reared at 25°C under 12 hr/12 hr light/dark cycles on standard oatmeal and molasses medium ([@bib19]). Details on fly strains used in this study are presented in the key resources table and detailed genotypes are included in corresponding figure legends.

For assessment of tumour volume and tumour cell death, flies were transferred to medium embryo collection cages and allowed to lay eggs for 8 hr at room temperature (RT) on agar/grape juice plates (2.1% agar, 25% grape juice, 1.25% sucrose, 0.2% methyl 4-hydroxybenzoate) supplemented with yeast paste. Plates were kept at 25°C until hatching. 200 larvae hatched within a 4 hr time window were collected and transferred to rearing bottles containing 45 mL of fly food to avoid any developmental delay and/or starvation effects due to overcrowding conditions. The tumour phenotype was analysed close to the normal developmental time, i.e. 7 days after hatching. Tumours were dissected and stained for further analysis (see below).

Generation of *defensin* mutants {#s4-2}
--------------------------------

*def^sk3^* and *def^sk4^* mutants were generated using CRISPR/cas9 technology ([@bib23]). Mutants were isogenised through backcrosses with a *w^1118^ iso* line as previously described in [@bib20].

Survival assays {#s4-3}
---------------

Survival of *def^SK3^* animals was compared to wild type controls (isogenised background, *iso*). Male flies (5--7 days old) were pricked in the thorax with a needle dipped in a concentrated pellet of fresh overnight bacterial culture. Infected flies were kept at 29°C. *Listeria innocua* was cultured in Brain heart infusion medium at 37°C and used at optical density of 200 nm (OD~600~). *Erwinia carotovora carotovora 15* was cultured in Luria-Bertani broth at 29°C and used at OD~600~ 200. Experiments were repeated three times independently and one representative experiment is shown.

Immunohistochemistry {#s4-4}
--------------------

Tissues were dissected in Phosphate Buffer Saline (PBS) and fixed for 20 min in 4% formaldehyde. Fat body samples were fixed for 30 min using the same protocol. Tissues were washed three times in PBS containing 1% of Triton-X100 (PBT) and incubated overnight at 4°C with primary antibodies. Tissues were washed five times in PBT and incubated for 2 hr at RT with secondary antibodies and 4',6-Diamidine-2′-phenylindole dihydrochloride (DAPI). After three washes in PBT, tissues were mounted in Vectashield using Secured-Seal spacers (Thermo Fisher Scientific).

Confocal images were captured using a Zeiss 710 or Zeiss 880 with Airyscan confocal microscope and processed with Fiji 2.0.0 or Adobe Photoshop C.S5.1.

Quantification of tumour volume and tumour cell death {#s4-5}
-----------------------------------------------------

For analysing tumour phenotype, images were acquired using optimal slice parameter and 12bits using a Zeiss 710 confocal microscope. Quantifications were made as previously described ([@bib45]). Briefly, we used Volocity 3D imaging analysis software to quantify the total volume of tumour identified by DAPI staining and cell death visualised with anti-Dcp1 staining. When haltere or leg discs tumours were still associated with the wing disc, they were not considered for quantification. Quantifications were done in at least three independent biological replicates for each genetic setting. Single representative experiments are presented except for *dlg;def* double mutant rescue experiments ([Figure 2K--L](#fig2){ref-type="fig"}) for which replicates are pooled due to the few larvae available. In all cases the difference between control and mutant tumour were strongly reproducible between replicates.

Quantification of colocalisation between Def and Dcp1 or Annexin V {#s4-6}
------------------------------------------------------------------

To quantify Def/Dcp-1 and Def/Annexin V colocalisation, we determined the intensity of Def staining in areas of positive versus negative staining for the second marker using the ImageJ macro, BatchQuantify ([@bib32]).

Sterile rearing conditions {#s4-7}
--------------------------

To rule out any effect of infection on the tumour phenotypes, *Drosophila* larvae were reared on standard food supplemented with penicillin and streptomycin when indicated in the figure.

qRT-PCR analysis {#s4-8}
----------------

Total RNA from 7 to 10 whole larvae or tissues collected from 10 to 20 larvae (10 larvae for fat body, 20 larvae for trachea) was extracted using TRIzol according to the manufacturer's instructions. RNA was treated with Turbo DNA free Kit and RNA concentration and quality were monitored using a Nanodrop (Thermo Fisher Scientific). The same amount of total RNA (1 μg for whole larvae and fat body or 100 ng for trachea) was used to perform the three independent reverse-transcriptions using the High-Capacity cDNA Reverse Transcription Kit. cDNAs were pooled and qPCR was performed using PerfeCTa SYBR green following the manufacturer's instructions. cDNA amplification was monitored with Applied Biosystems 7500 fast instruments. Serial 10-fold dilutions of an external standard were used to produce a standard curve, and RNA samples were included to control for the absence of DNA contamination. *rpl32* expression was used to normalise expression levels of target genes. Data was analysed using the Ct method (2^-∆∆ct^). All qPCR experiments were carried out on three to seven independent biological replicates (see figure legends for details) and, larvae were sampled from the same bottle used to analyse the tumour phenotype. GraphPad Prism7 software was used for graphical representation and statistical analysis. Primer targets and sequences are presented in key resources table.

PCR amplification of genomic DNA {#s4-9}
--------------------------------

To verify the sequence of *def^sk3^* and *def^sk4^* mutants, genomic DNA was extracted from single flies by grinding whole animals with a 200 μL pipette tip containing 50 μL of squishing buffer (10 mM Tris-HCl pH 8.2, 1 mM EDTA, 25 mM NaCl, 200 μg proteinase K) followed by incubation at 37°C for 30 min. Proteinase K was heat-inactivated at 95°C for 2 min. 1 μL of genomic DNA was used for PCR amplification using PfuUltra II Fusion DNA Polymerase and Eppendorf Mastercycler Ep Gradient Thermal Cycler.

Annexin V staining and quantification {#s4-10}
-------------------------------------

Tumours were dissected in PBS and incubated in Annexin V binding buffer containing 5% of Alexa Fluor (488 nm or 568 nm) conjugated Annexin V for 10 min. Tissues were washed quickly in Annexin V binding buffer and fixed in 4% formaldehyde for 20 min. Immunostaining, mounting and imaging were then carried out as described above.

We used Fiji 2.0.0 software to quantify Annexin V staining at the tumour surface. Maximal Z-projection of whole tumours were generated and the Colour Threshold tool was then used to detect the red pixels that represented Annexin V staining at the surface of tumours. The hue slider was set to include only the red signal, and the brightness slider was adjusted to exclude any background signal. This area was then selected and measured in pixels.

Synthetic defensin production and injections {#s4-11}
--------------------------------------------

The mature Defensin peptide was synthesised (over 90% purity) and the purity controlled by Genepep using Ultra Performance Liquid Chromatography/Mass Spectrometry. We subsequently compared the integrity of synthetic Defensin with authentic Defensin purified from *Drosophila* hemolymph using two complementary approaches, namely Matrix-Assisted Laser Desorption/Ionisation-Mass Spectrometry (MALDI-MS) for molecular mass determination and trypsin digestion followed by nanoLiquid Chromatography/Electrospray Ionisation tandem Mass Spectroscopy (nano*LC/ESI MS/MS*) for molecular integrity confirmation. Those analyses confirmed the similar mass between natural and synthetic Defensin (respectively provided by Bulet EIRL and Genepep) as well the presence of disulphide bonds within synthetic Def, demonstrating it is the mature peptide (Data not shown).

For injection experiments, larvae were collected, washed three times in cold sterile PBS and injected on a fly pad upon CO~2~ anaesthesia using Nanoject II (Drummond) and glass capillaries 3.5 inch (Drummond). Larvae were injected with 69 nL of PBS containing 7.5 nmol of synthetic Defensin or 69 nL of PBS only as control. Larvae were then gently transferred into agar/grape juice plates and kept at 25°C. Tumours were dissected 4 hr after injection and stained for visualisation of nuclei and tumour cell death as describe above.

Statistical analyses {#s4-12}
--------------------

All data are presented as mean ± SD and n values are indicated in the figure legends. Statistical analyses were carried out using GraphPad Prism7 software and only significant differences are indicated in dot-plots. Survival upon infection was analysed using Log-rank test. qPCR data were analysed using unpaired t-test with a two-tailed p value. Tumour volume and tumour cell death comparing two samples were analysed using Mann-Whitney test with a two-tailed p value and the one comparing three genotypes were analysed using One-way ANOVA followed by Turkey's multiple comparisons test. Tumour volume from injected larvae was analysed using Two-way ANOVA followed by Turkey's multiple comparisons test and only significant statistical differences between ctrl and Defensin injected larvae for each genotype tested are indicated.

Data and material availability {#s4-13}
------------------------------

All raw data is available through <http://dx.doi.org/10.5525/gla.researchdata.834>.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The antimicrobial peptide Defensin cooperates with Tumour Necrosis Factor to drive tumour cell death in *Drosophila*\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Utpal Banerjee as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Georg Halder (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This is an interesting manuscript about a topic of wide significance. The authors investigate the role of the antimicrobial peptide defensin in killing tumour cells in a *Drosophila* cancer model. They report that defensin is secreted by the fat body and trachea in response to Toll and Imd signalling and that defensin kills tumour cells by binding to cell surface phosphatidylserine, which become exposed in response to TNF signalling. This is novel and, if true, may provide the foundation of new approaches to understanding cell death and growth control in tumours.

For a rather radical proposal, the data need to be solid. In general, the results are convincing and carefully controlled but here are a few that are very important to the model but are not as convincing (or at least not as clearly presented) as most of the others. The reviewers\' consensus is that the following issues need to be addressed before this paper could be accepted by *eLife*.

1\) In Figure 4E they claim to show that humoral defensin is binding to \'transformed imaginal discs\' in *dlg* mutant animals. This figure is hard to interpret. Tumour tissue seems to be marked by anti-Dcp1, a cell death marker, but it\'s not clear whether this marks the whole tumour. Moreover, the HA-defensin staining is very limited and does not obviously colocalise with Dcp1 or anything else. The idea that defensin binds to tumour tissue is central to the model 4E does not strongly support the idea. To be fair, the other data in Figure 4 are clearer and more convincing, but 4E is a problem. It would be better to show an image of the whole disc first so that we can appreciate the morphology and also how the staining looks over an entire tumour and not only in a small selected region. It would also be good to show the individual channels of 4G and to comment on the amount of non-overlap that is present.

2\) Aspects of Figure 7, which is central to the conclusion that defensin binds to exposed PS on tumour cells, are also of concern. Panels A purport to show that defensin colocalises with annexin V, a marker of exposed PS, but the images do not show that convincingly. It is clear in A\' and A\' that there is plenty of non-overlap between the green annexin and red defensin. Much red defensin appears to label annexin-negative tissue. Without clearer data, preferably quantified, it is hard to support the conclusion.

3\) The model that JNK activation is a prerequisite for defensin mediated tumour cell killing is of particular interest, as AMPs lack strong specificity towards killing cancer cells. However, since the experiments were done in *egr* mutants, which is a secreted protein that activates JNK signalling, it is not clear whether the requirement for JNK activation is in tumour cells and/or other cells. JNK could just as well act non-autonomously and this experiment would distinguish whether their model is correct or not. To further investigate this, the authors should test the effect of defensin overexpression on the efficacy of JNK induced cell death. This might best be done in clones with weak JNK activation, e.g. puckered hypomorphic clones. However, a scenario of double overexpression of defensin with a construct to activate JNK may be sufficient.

4\) It is notable that the data in Figure 7C shows that the statistical confidence of the differences is rather low.

5\) Both the written description and the diagrams in Figures 1 and 7 of the complex signalling between tumour cells, haemocytes, FB and trachea, involving TNF, Toll, Imd, and defensin, are complex and hard to follow. Of course this is partly because biology is complicated, but a better job could be done. It is important that readers do understand both the anatomical and the signalling aspects of the model.
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Author response

> \[...\] For a rather radical proposal, the data need to be solid. In general, the results are convincing and carefully controlled but here are a few that are very important to the model but are not as convincing (or at least not as clearly presented) as most of the others. The reviewers\' consensus is that the following issues need to be addressed before this paper could be accepted by eLife.
>
> 1\) In Figure 4E they claim to show that humoral defensin is binding to \'transformed imaginal discs\' in dlg mutant animals. This figure is hard to interpret. Tumour tissue seems to be marked by anti-Dcp1, a cell death marker, but it\'s not clear whether this marks the whole tumour. Moreover, the HA-defensin staining is very limited and does not obviously colocalise with Dcp1 or anything else. The idea that defensin binds to tumour tissue is central to the model 4E does not strongly support the idea. To be fair, the other data in Figure 4 are clearer and more convincing, but 4E is a problem. It would be better to show an image of the whole disc first so that we can appreciate the morphology and also how the staining looks over an entire tumour and not only in a small selected region. It would also be good to show the individual channels of 4G and to comment on the amount of non-overlap that is present.

The goal of Figure 4E was to unambiguously show that none-tumour produced Def (fat body overexpressed Def-HA) binds to tumours but not wild type tissues (old Figure 4F, F'). As the reviewer pointed out, the assessment of endogenous Def in tumours does supports the selective binding of the AMP to the tumours (new Figure 4D-H''). However, the reviewer is correct in that old Figure 4E was not clear enough to make the case for Def tumour binding and/or Dcp-1 co-localization. One of the issues is that, in addition to the tumour itself, tumour associated tissues, which are negative for Dcp-1 but produce Defensin (fat body and trachea) are almost always captured in these images. Def expression in such accessory tissues is obviously more robust in the context of Def-HA overexpression (Figure 4---figure supplement 1). We now provide new and significantly improved images of a whole tumour and zoomed-in areas of tumour tissue, including individual channels (new Figure 4A-B''). For completeness, we also present quantifications, which confirm enrichment of endogenous Def in Dcp-1^+ve^ areas on the tumours (new Figure 4F). For organisational purposes, pictures depicting basal UAS-Def-HA expression patterns and following fat body overexpression in wild type discs (old Figure 4A-D) are now in a new Figure 4---figure supplement 1.

Furthermore to unambiguously demonstrate the specificity of ectopically produced Def to bind to tumours exposing PS, we overexpressed Def-HA in the fat body of *dlg^40.2^;egr^3/3^* animals (new Figure 7---figure supplement 1A, B). *dlg^40.2^;egr^3/3^* tumours don't expose PS and are refractive to Def killing action (Figures 7G and K). Consistently, they present no detectable staining for Def-HA (new Figure 7---figure supplement 1C, C').

> 2\) Aspects of Figure 7, which is central to the conclusion that defensin binds to exposed PS on tumour cells, are also of concern. Panels A purport to show that defensin colocalises with annexin V, a marker of exposed PS, but the images do not show that convincingly. It is clear in A\' and A\' that there is plenty of non-overlap between the green annexin and red defensin. Much red defensin appears to label annexin-negative tissue. Without clearer data, preferably quantified, it is hard to support the conclusion.

As for the previous point we now present quantification of Def and AnnexinVco-localization (new Figure 7C). We also present individual channels for a more clear visualization of Annexin V and Def staining (new Figure 7A-A'' and B-B''). As noted by the reviewer, there are tumour areas stained with Def and not AnnexinV and vice versa. However, our data from images and quantifications clearly shows an enrichment of Def within AnnexinV^+ve^ versus AnnexinV^-ve^ tumour areas. Moreover, a new experiment showing that Def-HA can't associate to *dlg^40.2^;egr^3/3^* tumours also support this conclusion (see above and new Figure 7---figure supplement 1C, C').

> 3\) The model that JNK activation is a prerequisite for defensin mediated tumour cell killing is of particular interest, as AMPs lack strong specificity towards killing cancer cells. However, since the experiments were done in egr mutants, which is a secreted protein that activates JNK signalling, it is not clear whether the requirement for JNK activation is in tumour cells and/or other cells. JNK could just as well act non-autonomously and this experiment would distinguish whether their model is correct or not. To further investigate this, the authors should test the effect of defensin overexpression on the efficacy of JNK induced cell death. This might best be done in clones with weak JNK activation, e.g. puckered hypomorphic clones. However, a scenario of double overexpression of defensin with a construct to activate JNK may be sufficient.

This is indeed a very interesting question. However, we would like to point that, our data definitely suggests that Egr and PS exposure, which is dependent on Egr, are a pre-requisite for Def killing of tumour cells. Even though Egr does activate JNK signaling, it may also be doing more than that in these tumours. In order to best address the reviewer's question following his/her line of thought and with the tools that were available to us to perform experiments within the timeframe of this revision we did the following:

1- To achieve mild JNK activation as we successfully did in other contexts (Cordero et al., 2012), we overexpressed wild type JNK. Here, we used *engrailed-gal4 (eng\>hep^wt^*) and analysed wing discs. This condition, led to mild apoptosis in the wing pouch but was not sufficient to drive detectable PS exposure ([Author response image 1A-D](#respfig1){ref-type="fig"}). Therefore, and consistently with our model (PS exposure is required for Def killing), the administration of injected recombinant Def or genetic co-expression of UAS-Def did not modify JNK-dependent cell death ([Author response image 1C, D](#respfig1){ref-type="fig"}).

2- Given the mild basal phenotype obtained by overexpressing wild type JNK and following the second suggestion by the reviewer "a scenario of double overexpression of defensin with a construct to activate JNK may be sufficient*".* We overexpressed activated *hemipterous* using *rotund-gal4 (rn\>hep^act^*) as *eng\>hep^act^* led to embryonic lethality. However, *rn\>hep^act^*discs presented a complete apoptosis of the wing pouch, and consistently extremely rare adult escapers were devoid of wings ([Author response image 2](#respfig2){ref-type="fig"} and data not shown). We reasoned that a quantifiable assessment of a potential enhancement of this phenotype was not going to be possible.

As per the results with *hep^wt^*, we can conclude that a mild activation of JNK in an otherwise wild type tissue is not sufficient to allow apoptosis by Defensin. Nonetheless, we cannot exclude that an intermediate, sublethal, activation of the JNK pathway might lead to Def sensitivity. Alternatively, and given the absolute need of Egr for PS exposure for the Def anti-tumoural role, it is conceivable that the role of Egr in these tumours extends beyond activation of JNK. We have integrated these results in the revised Discussion of our manuscript.

![Anti-tumoural immunity in flies: the key players.\
(**A, B**) Third instar larval imaginal wing disc overexpressing of *hep^wt^* using *engrailed-gal4, UAS-rfp (eng\>rfp; hep^wt^*) (**A**; red). Discs where stained with AnnexinV to visualize PS exposure (**B**; green). (**C**) Assessment of apoptotic cell death in wing discs from *eng\>rfp; hep^wt^*animals injected with PBS (control) or recombinant Defensin. (**D**) Assessment of apoptotic cell death in wing discs from animal following overexpression of *hep^wt^*only, *def* only, or co-expression of both transgenes using combined *eng-gal4* and *lpp-gal4* drivers.](elife-45061-resp-fig1){#respfig1}

![Anti-tumoural immunity in flies: the key players.\
(A, B) Third instar larval imaginal wing disc overexpressing of *hep^act^* using *rutond-gal4 (rn\>hep^act^*).\
Discs where stained with anti-Dcp1 to visualize apoptotic cell death (B; red).](elife-45061-resp-fig2){#respfig2}

> 4\) It is notable that the data in Figure 7C shows that the statistical confidence of the differences is rather low.

This is a fair point. Reasons for this are likely due to the variability in *def* expression levels within the *dlg* animals. Moreover, we have done ANOVA to compare multiple samples in old Figure 7C (new Figure 7D), which is more stringent than T-test used in other cases in the manuscript where we compared only two sets of RT-QPCR data (e.g. Figure 1B). Therefore, even \* is meaningful. Importantly, we do present several lines of evidence on the functional importance of Egr in the system.

> 5\) Both the written description and the diagrams in Figures 1 and 7 of the complex signalling between tumour cells, haemocytes, FB and trachea, involving TNF, Toll, Imd, and defensin, are complex and hard to follow. Of course this is partly because biology is complicated, but a better job could be done. It is important that readers do understand both the anatomical and the signalling aspects of the model.

We have now simplified the diagrams (new Figure 1A and Figure 7L) and text to focus on the key points addressed in this manuscript.
